MedTrace Logo

Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair

NCT02168439 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-11-14

Study results available
· View outcomes & findings →

Summary

The objective of this research study is to show superiority of intranasal dexmedetomidine to intranasal midazolam as anxiolysis prior to pediatric laceration repairs.

Conditions

Interventions

DRUG

Dexmedetomidine

DRUG

Midazolam

Sponsors & Collaborators

  • University of Pittsburgh Clinical and Translational Science Institute (CTSI)

    collaborator UNKNOWN

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Desiree Neville, MD · Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-04-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02168439 on ClinicalTrials.gov